Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15687494 | 0.87 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL15687466 | 0.86 | L3MBTL1 (0.42) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL15687675 | 0.84 | ADRB1 (0.39) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL15687467 | 0.81 | PDE2A (0.37) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL12523256 | 0.81 | TSHR (0.43) | NOTUML3MBTL1TSHRARALDH1A1 | |
| SCHEMBL15687492 | 0.81 | NOTUM (0.34) | ADRB1NOTUML3MBTL1TSHRALDH1A1 | |
| SCHEMBL9821254 | 0.80 | ADRB1 (0.54) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL9821038 | 0.79 | ADRB2 (0.51) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL9003991 | 0.77 | GABRA1 (0.40) | LMNANOTUML3MBTL1TSHRAR | |
| SCHEMBL954835 | 0.77 | CES2 (0.47) | ADRA2AADRA2BADRA2CADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339402-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| EP-4511355-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FundaMental Pharma GmbH (DE) | 2025-02-26 | — | — | EP | disclosed |
| CN-119522208-A | Effective methods for modulating NMDA receptor-mediated toxicity | 智基药业有限公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2024223617-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2024-10-31 | — | — | WO | disclosed |
| WO-2023203254-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023203254-A2 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339402-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | TRPM4, GRM4, GRIN1 | ADRA2A 1777/4885ADRA2B 1418/4885ADRA2C 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.